MetaVia reports Q3 EPS (14c), consensus (25c)

Cash was $14.3M as of September 30 vs. $16.0M as of December 31, 2024. The company expects its cash position will be adequate to fund operations into 2026. “During Q3 and subsequently, we continued to make strong progress advancing our next-generation cardiometabolic portfolio, highlighted by the Phase 1 data for DA-1726 presented just recently at ObesityWeek 2025,” stated CEO Hyung Heon Kim. “….As previously reported, the 32 mg cohort demonstrated a strong safety and tolerability profile without the need for titration, along with potentially best-in-class weight loss and waist circumference reduction…Based on these encouraging findings, during the quarter we extended the Phase 1 study to include an 8-week, 48 mg cohort to assess longer-term efficacy, safety, and the non-titrated maximum tolerated dose. We expect to report results from this cohort by year-end, which will help inform the next stage of development and further demonstrate DA-1726’s potential as a best-in-class treatment for obesity. With regard to our second asset, vanoglipel or DA-1241, a first-in-class oral GPR119 agonist, the 16-week Phase 2a results demonstrated meaningful reductions in liver fat, inflammation and fibrosis – three key drivers of MASH progression…Additionally, we are preparing for an end-of-Phase 2 meeting with the FDA during the first half of 2026 to discuss the next stage of clinical development.”